Results 211 to 220 of about 267,329 (233)

A 53-week, open-label phase IIIb study of velaglucerase alfa in Chinese patients with type 1 Gaucher disease: Safety, efficacy, and pharmacokinetics. [PDF]

open access: yesMol Genet Metab Rep
Zhang L   +11 more
europepmc   +1 more source

Real-world use of pegylated erythropoietin in CKD-related anemia: an Indian modified Delphi consensus. [PDF]

open access: yesFront Nephrol
Kher V   +13 more
europepmc   +1 more source

TRIM21 Neutralizes Hazara Virus Using a Dual Mechanism of Nucleoprotein Caging and Ubiquitination. [PDF]

open access: yesViruses
Jahun AS   +5 more
europepmc   +1 more source
Some of the next articles are maybe not open access.

Related searches:

Impact of Alfa fibers morphology on hydration kinetics and mechanical properties of cement mortars

Construction and Building Materials, 2021
Jonathan Page   +2 more
exaly  

Potential use of Alfa fibers in construction material: Physico-mechanical and thermal characterisation of reinforced specimen

Construction and Building Materials, 2022
Ezeddine Sediki
exaly  

Use of peginterferon alfa-2a (40 KD) (Pegasys) for the treatment of hepatitis C

Advanced Drug Delivery Reviews, 2002
Rajender Reddy
exaly  

Physico-chemical properties and thermal stability of microcrystalline cellulose isolated from Alfa fibres

Carbohydrate Polymers, 2014
Nicolas Brosse   +2 more
exaly  

A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE)

Journal of Hepatology, 2006
Mark Laughlin
exaly  

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

Lancet, The, 2001
Mitchell Shiffman   +2 more
exaly  
editorial
fad stu
enterobacterales
research
omega
previous   20  21  22  23  24  

Home - About - Disclaimer - Privacy